Shares of MannKind (NASDAQ:MNKD), the biotechnology company behind the revolutionary ... Covering analyst Joshua Schimmer downgraded his firm's rating on the stock to "underweight" from "neutral," and reduced …
The Motley Fool · BySean Williams · 10/6/2015
(TheStreet) -- The deadline for MannKind (MNKD) to settle debt totaling $32 million passed ... It's possible, but unlikely, that MannKind convinced some of its debt holders to accept company stock. MannKind CFO Matt …
The Street · ByAdam Feuerstein · 10/5/2015
On Tuesday, Benzinga spoke with Diabetic Investor David Kliff about MannKind Corporation (NASDAQ: MNKD), after he said in a tweet ... "there's a reason why so many people are short this stock." Disclosure: Javier …
Yahoo Finance · 9/30/2015
Diabetic Investor
More from Bing News
MNKD has shed more than two-fifths of its value in 2015. In fact, the shares hit a two-year low of $2.98 last Friday, and were last seen lingering near $3.08. The stock could be poised to extend these losses, should …
Schaeffer's Investment Research · ByKaree Venema · 1 day ago
United Therapeutics Corp (UTHR): UTHR stock is down 3.2% today on 2 times normal volume. Mannkind Corp (MNKD): MNKD stock is down 2.7% today. Biomarin Pharmaceutical Inc (BMRN): BMRN stock is down 2.7% today. Opko Health Inc (OPK) …
Investor Place · 10/5/2015
MannKind (NASDAQ:MNKD) was upgraded by Zacks from a “hold” rating to a “buy” rating in a research note issued on Tuesday, Analyst Ratings.Net reports. The firm currently has a $3.50 price target on the biopharmaceutical company’s stock.
Ticker Report · 9/29/2015
Zacks upgraded shares of MannKind (NASDAQ:MNKD) from a hold rating to a buy rating in a research report released on Tuesday, MarketBeat reports. Zacks currently has $3.50 price target on the biopharmaceutical company’s stock. According to Zacks ...
Mideast Times · 10/2/2015
A time when a stock you owned just dropped off a cliff or when you sold a stock right before it took off. For me, my major regret story involves MannKind (NASDAQ:MNKD). My father first introduced me to the stock market when I was about 16 years old.
Seeking Alpha · 6/3/2015
The stock closed at $1.72 on Thursday, and the 52-week range is $1.61 to $3.72. MannKind Corp.’s (NASDAQ: MNKD) short interest, at around 126.66 million shares as of September 15, was likewise about the same …
24/7 Wall ST · 9/25/2015
short interest
This is a way for manipulation to occur and can come with big consequences for any stock. Unfortunately for MannKind, short interest on the stock is way up. Currently, about 45% of shares are sold short, which is an astronomical figure. However ... · 9/8/2015